Ocular Therapeutix, Inc (OCUL): who owns it and who trades it
As of Nov 16, 2026, OCUL insiders reported 29 open-market sales worth $3.3M and 1 purchase worth $461K in the last 12 months, with 93% of the sale value made under pre-set 10b5-1 plans. The largest seller was Pravin Dugel (Director), with $1.9M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ocular Therapeutix
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns OCUL
262 funds and institutions reported OCUL shares worth $2B at the end of Q2 2026, about 95% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 32.84M | 15.00% | $323M | +1% |
| Deep Track Capital, LP | 19.69M | 8.99% | $193M | No change |
| BlackRock, Inc. | 19.38M | 8.85% | $190M | +20% |
| Avoro Capital Advisors LLC | 12.54M | 5.73% | $123M | +2% |
| Summer Road LLC | 12.21M | 5.58% | $120M | +3% |
| Venrock Adviser, LLC | 10.35M | 4.73% | $102M | No change |
| Vanguard Capital Management LLC | 8.83M | 4.03% | $86.7M | +1% |
| T. Rowe Price Associates | 7.62M | 3.48% | $74.9M | +29% |
| Logos Global Management LP | 5.30M | 2.42% | $52M | +38% |
| State Street Corp | 5.23M | 2.39% | $51.4M | +11% |
| Geode Capital Management, LLC | 5.02M | 2.29% | $49.3M | +11% |
| Point72 Asset Management, L.P. | 3.29M | 1.50% | $32.3M | -41% |
| Dimensional Fund Advisors LP | 2.78M | 1.27% | $27.3M | +328% |
| Deltec Asset Management LLC | 2.48M | 1.13% | $24.3M | +6% |
| Balyasny Asset Management L.P. | 2.27M | 1.04% | $22.3M | -16% |
| Octagon Capital Advisors LP | 2.08M | 0.95% | $20.4M | -34% |
| Vanguard Portfolio Management LLC | 1.97M | 0.90% | $19.4M | +24% |
| Northern Trust Corp | 1.80M | 0.82% | $17.7M | +18% |
| Goldman Sachs Group Inc | 1.76M | 0.80% | $17.3M | +59% |
| Nuveen, LLC | 1.70M | 0.78% | $16.7M | +313% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, OCUL insiders reported $461K of open-market purchases and $3.3M of sales. 93% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Namrata Saroj | Chief Business Officer | Sale plan | 35,370 | $6.55 | $232K | Form 4 |
| Oct 8, 2026 | Todd Anderman | Chief Legal Officer | Sale plan | 11,984 | $7.29 | $87.4K | Form 4 |
| Oct 2, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale plan | 10,869 | $7.05 | $76.6K | Form 4 |
| Oct 2, 2026 | Peter Kaiser | Chief Development Office | Sale plan | 9,990 | $7.05 | $70.4K | Form 4 |
| Aug 31, 2026 | Donald Notman | Chief Operating Officer | Sale | 1,099 | $10.24 | $11.3K | Form 4 |
| Aug 24, 2026 | Peter Kaiser | Chief Development Office | Sale plan | 3,035 | $10.77 | $32.7K | Form 4 |
| Aug 24, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale plan | 1,897 | $10.78 | $20.4K | Form 4 |
| Aug 24, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale plan | 3,296 | $10.78 | $35.5K | Form 4 |
| Aug 24, 2026 | Pravin Dugel | Director | Sale plan | 21,649 | $10.77 | $233K | Form 4 |
| Jun 3, 2026 | Nadia Waheed | Chief Medical Officer | Sale plan | 14,828 | $8.27 | $123K | Form 4 |
| May 26, 2026 | Pravin Dugel | Director | Sale plan | 21,156 | $8.20 | $173K | Form 4 |
| May 26, 2026 | Peter Kaiser | Chief Development Office | Sale plan | 2,967 | $8.20 | $24.3K | Form 4 |
| May 26, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale plan | 3,018 | $8.20 | $24.7K | Form 4 |
| May 26, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale plan | 1,858 | $8.20 | $15.2K | Form 4 |
| Feb 23, 2026 | Pravin Dugel | Director | Sale plan | 20,056 | $8.28 | $166K | Form 4 |
| Feb 23, 2026 | Peter Kaiser | Chief Development Office | Sale plan | 2,810 | $8.28 | $23.3K | Form 4 |
| Feb 23, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sale plan | 3,057 | $8.28 | $25.3K | Form 4 |
| Feb 23, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale plan | 1,759 | $8.28 | $14.6K | Form 4 |
| Feb 20, 2026 | Nadia Waheed | Chief Medical Officer | Sale plan | 3,510 | $7.74 | $27.2K | Form 4 |
| Feb 20, 2026 | Richard L Md Lindstrom | Director | Purchase | 60,229 | $7.66 | $461K | Form 4 |
| Feb 12, 2026 | Donald Notman | Chief Operating Officer | Sale | 11,446 | $9.04 | $103K | Form 4 |
| Feb 12, 2026 | Sanjay Nayak | Chief Strategy Officer | Sale plan | 10,348 | $9.04 | $93.5K | Form 4 |
| Feb 12, 2026 | Pravin Dugel | Director | Sale plan | 124,882 | $9.04 | $1.1M | Form 4 |
| Feb 12, 2026 | Nadia Waheed | Chief Medical Officer | Sale plan | 7,863 | $9.04 | $71.1K | Form 4 |
| Feb 4, 2026 | Donald Notman | Chief Operating Officer | Sale | 6,035 | $8.54 | $51.5K | Form 4 |
| Feb 2, 2026 | Donald Notman | Chief Operating Officer | Sale | 5,455 | $9.14 | $49.9K | Form 4 |
| Nov 24, 2025 | Sanjay Nayak | Chief Strategy Officer | Sale plan | 1,878 | $12.04 | $22.6K | Form 4 |
| Nov 24, 2025 | Pravin Dugel | Director | Sale plan | 19,530 | $12.04 | $235K | Form 4 |
| Nov 24, 2025 | Peter Kaiser | Chief Development Office | Sale plan | 3,007 | $12.02 | $36.1K | Form 4 |
| Nov 24, 2025 | Jeffrey S. Heier | Chief Scientific Officer | Sale plan | 3,469 | $12.04 | $41.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Pravin Dugel | See Remarks, Director | – | $1.9M | Aug 24, 2026 |
| Richard L Md Lindstrom | Director | $461K | – | Feb 20, 2026 |
| Namrata Saroj | Chief Business Officer | – | $232K | Nov 5, 2026 |
| Nadia Waheed | Chief Medical Officer | – | $221K | Jun 3, 2026 |
| Donald Notman | Chief Operating Officer | – | $216K | Aug 31, 2026 |
| Jeffrey S. Heier | Chief Scientific Officer | – | $204K | Oct 2, 2026 |
| Peter Kaiser | Chief Development Officer | – | $187K | Oct 2, 2026 |
| Sanjay Nayak | Chief Strategy Officer | – | $166K | Aug 24, 2026 |
| Todd Anderman | Chief Legal Officer | – | $87.4K | Oct 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OCUL short interest
High short interest. 13.2% of OCUL shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 17%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 29.00M OCUL shares were sold short, 13.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 10.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 29.00M | 13.20% | +1% | 2.86M | 10.1 |
| Oct 15, 2026 | 28.76M | 13.10% | -2% | 3.55M | 8.1 |
| Sep 30, 2026 | 29.41M | 13.39% | -2% | 4.06M | 7.2 |
| Sep 15, 2026 | 29.93M | 13.63% | +7% | 2.11M | 14.2 |
| Aug 31, 2026 | 28.06M | 12.77% | -2% | 3.13M | 9.0 |
| Aug 14, 2026 | 28.52M | 12.98% | +7% | 2.25M | 12.7 |
| Jul 31, 2026 | 26.74M | 12.17% | -1% | 1.98M | 13.5 |
| Jul 15, 2026 | 27.03M | 12.34% | +1% | 2.07M | 13.1 |
| Jun 30, 2026 | 26.70M | 12.19% | +1% | 4.07M | 6.6 |
| Jun 15, 2026 | 26.46M | 12.08% | +5% | 2.23M | 11.8 |
| May 29, 2026 | 25.09M | 11.46% | +1% | 2.77M | 9.0 |
| May 15, 2026 | 24.78M | 11.32% | -0% | 2.92M | 8.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ocular Therapeutix company events
Ocular Therapeutix filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026LeadershipThe Board of Directors of Ocular Therapeutix, Inc., following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately. Filing
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 16, 2026LeadershipSanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc., notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jun 12, 2026LeadershipOcular Therapeutix, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 27, 2026AnnouncementShared information with investors. Filing
- Feb 5, 2026ResultsReleased financial results. Filing
- Jan 23, 2026LeadershipDonald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc., is taking a temporary medical leave of absence from the Company. Filing
- Dec 18, 2025AnnouncementAs the Company prepares for database lock for its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration, the Company is entering a quiet period beginning December 20, 2025. Filing
- Dec 5, 2025AnnouncementThe U.S. Food and Drug Administration has historically required two adequate and well-controlled clinical trials to demonstrate the safety and efficacy of ophthalmic product candidates, in particular for larger indications such as wet age-related macular degeneration. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ocular Therapeutix financials
Famous investors that hold OCUL
3 of the 50 well-known investors we track reported holding OCUL in their latest 13F filing. The largest position is Jim Simons's, worth $4.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 540,900 | $4.1M | 0.0% | +43% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 441,769 | $3.4M | 0.0% | +42% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 283,555 | $2.2M | 0.0% | -91% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Ocular Therapeutix, Inc (OCUL) stock
Who owns the most OCUL stock?
The largest reported owner of Ocular Therapeutix, Inc (OCUL) is FMR LLC (Fidelity), with 15.0% of the company. In total, 262 funds and institutions reported holding OCUL at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are OCUL insiders buying or selling?
In the last 12 months, OCUL insiders reported 1 open-market purchase worth $461K and 29 sales worth $3.3M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in OCUL?
As of Oct 30, 2026, 29.00M OCUL shares were sold short, 13.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 10.1 trading days (days to cover). See the history.
Which famous investors hold OCUL?
3 of the 50 well-known investors we track reported OCUL in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $4.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.